Neuroinflammation and brain health: what the evidence really says
Neuroinflammation is the activation of the brain's own immune cells, the microglia and astrocytes. In short bursts it is protective: it clears debris, fights infection and helps repair. The concern is the chronic, low-grade version that can drift into a maladaptive state and is linked, with varying strength of evidence, to low mood, brain fog, fatigue and the slow biology of Alzheimer's. Most of what you read online overstates this: the firmest claims are mechanistic and from animal work, the strongest human levers are unglamorous (sleep, exercise, treating sleep apnoea, a Mediterranean-style diet), and almost all "anti-neuroinflammatory" supplements are sold far ahead of their evidence.
Key facts
- Microglia are the brain's resident immune cells; astrocytes are support cells that also drive inflammatory signalling. Both can be protective or harmful depending on context.
- The link between inflammation and depression is real but partial: in pooled longitudinal data, raised C-reactive protein (CRP) and interleukin-6 (IL-6) modestly predict later depressive symptoms, but the effect shrinks after adjusting for confounders.3
- Anti-inflammatory drugs help depression only modestly overall, and chiefly in people who actually have raised inflammation, not everyone.56
- In Alzheimer's, genetics put microglia at the centre: the TREM2 R47H variant raises late-onset risk roughly four to fivefold, implicating the brain's immune response in the disease, not just amyloid.9
- The best-supported ways to keep brain inflammation low are the same boring levers that help the rest of the body. The supplement aisle is mostly hype here.
- What neuroinflammation actually is
- Protective versus chronic, maladaptive inflammation
- Sickness behaviour: the everyday version
- The cytokine hypothesis of depression, honestly
- Memory, cognition and Alzheimer's
- The gut, the vagus nerve and the body-brain loop
- What raises brain inflammation
- What the evidence says helps, and what is just sold
- What to ask your GP and what to do next
What neuroinflammation actually is
The brain has its own immune system, kept somewhat separate from the body by the blood-brain barrier. Two cell types do most of the work. Microglia are the resident immune cells, derived early in development from the yolk sac rather than the bone marrow. They are not passive: even at rest they constantly extend and retract fine processes, sampling their surroundings, pruning unused synapses and clearing debris.1 When they detect injury, infection or abnormal proteins, they change shape and behaviour and release signalling molecules called cytokines.
Astrocytes are the brain's most numerous support cells. They feed neurons, manage the chemical environment and help maintain the blood-brain barrier. They also participate in inflammation: in a pro-inflammatory state they release cytokines such as IL-1 beta, TNF-alpha and complement proteins that can damage neurons and synapses, while in a protective state they secrete growth factors that aid survival and repair.1 Microglia and astrocytes talk to each other constantly, and the net effect on the brain depends on that crosstalk and on the wider context.
Crucially, "neuroinflammation" is not one thing. It is a spectrum of cell states, not a simple on or off switch, and the older language of fully "activated" versus "resting" microglia has been replaced by a more nuanced picture of many overlapping states. This matters when you read confident claims online: the science is genuinely subtle, and most of the precise mechanisms have been worked out in mice, not people.
Protective versus chronic, maladaptive inflammation
This is the single most important distinction in the field, and the one most often lost in popular coverage. Acute neuroinflammation is a feature, not a bug. After a head injury, a stroke or an infection, microglia and astrocytes mount a fast response that contains damage, clears dead cells and sets the stage for repair. Without it, the brain would heal far worse. Inflammation here is the fire brigade, not the fire.
The problem arises when this response fails to switch off. Chronic, low-grade neuroinflammation is the same machinery stuck on a low simmer, sustained by things like persistent metabolic stress, repeated infections, an ageing immune system or chronic psychological stress. In this state, microglia can become primed: quicker to overreact, slower to calm down, and capable of releasing cytokines and reactive molecules that, over years, may harm neurons and synapses rather than protect them. This is the version plausibly linked to mood, memory and fatigue. It is a close cousin of the body-wide process we cover in chronic inflammation explained, and the same drivers tend to feed both.
Evidence read: the protective-versus-chronic framing is well established mechanistically. What is far less certain in humans is exactly when, and in whom, ordinary low-grade inflammation tips into something that actively damages the brain. Be sceptical of anyone who talks as if "neuroinflammation" is a single measurable thing you can switch off with a pill.
Sickness behaviour: the everyday version
You have already felt low-grade neuroinflammation in action. Think of the last time you had flu: the low mood, the fog, the heavy fatigue, the loss of appetite and the urge to withdraw and sleep. That cluster is called sickness behaviour, and it is not incidental to being ill. It is an organised, brain-driven response, an evolved strategy to conserve energy and aid recovery.2
The trigger is inflammatory cytokines produced by the immune system, chiefly IL-1, IL-6 and TNF-alpha, signalling to the brain both through nerve pathways (notably the vagus nerve) and through diffusion at leaky points in the blood-brain barrier.2 Robert Dantzer and colleagues laid out this framework in an influential 2008 Nature Reviews Neuroscience review, arguing that when immune activation continues unabated, sickness behaviour can shade into something that looks like clinical depression in vulnerable people.2 One proposed route is the kynurenine pathway: cytokines push the amino acid tryptophan away from making serotonin and toward metabolites that affect glutamate signalling. This overlaps heavily with the everyday experience of inflammatory brain fog and fatigue.
The cytokine hypothesis of depression, honestly
The idea that inflammation contributes to depression is one of the most active areas in psychiatry, and also one of the most over-sold. Here is the honest version, separating what is reasonably established from what is not.
What is reasonably established. A subgroup of people with depression have measurably raised inflammatory markers. Giving people the cytokine interferon-alpha (an older treatment for hepatitis C and some cancers) triggers clinically significant depression in roughly a third of patients, which is about as close to a controlled human experiment as this field offers and strongly suggests inflammation can cause depressive symptoms, at least in some.4 And in longitudinal cohorts, higher CRP and IL-6 modestly predict later depressive symptoms.3
Where the limits are. The associations are small and not specific. A systematic review and meta-analysis of longitudinal studies found CRP and IL-6 did predict future depressive symptoms, but the effect was substantially attenuated once you adjusted for confounders such as body weight, smoking and chronic illness.3 Most people with depression do not have raised inflammation, most people with raised inflammation are not depressed, and the direction of cause runs both ways (low mood worsens sleep, diet and activity, which themselves raise inflammation).
The clearest test is whether anti-inflammatory drugs treat depression. The answer is a qualified, modest yes. A 2019 meta-analysis by Ole Köhler-Forsberg and colleagues in Acta Psychiatrica Scandinavica pooled 36 randomised trials and found anti-inflammatory agents (NSAIDs, cytokine inhibitors, statins and others) improved depressive symptoms versus placebo, especially as add-on therapy, though the trials were heterogeneous and many were small.5 Tellingly, when Charles Raison and colleagues tested the TNF blocker infliximab in treatment-resistant depression (JAMA Psychiatry, 2013), it did nothing overall, and only helped the subgroup who started with raised CRP (above 5 mg/L). In people with low inflammation it was slightly worse than placebo.6
| Claim | Evidence status | Honest reading |
|---|---|---|
| Some depressed people have raised inflammatory markers | Well supported | True for a subgroup, not the majority |
| Cytokines can cause depressive symptoms | Supported (interferon-alpha studies) | Shows it is possible, not that it is the usual cause |
| Raised CRP/IL-6 predicts future depression | Modest, attenuates after adjustment3 | A weak signal, heavily confounded |
| Anti-inflammatory drugs treat depression | Small overall effect; better in high-inflammation subgroups56 | Promising for stratified use, not a general treatment |
| "Depression is just inflammation" | Not supported | An overstatement; inflammation is one contributor among several |
None of this is a reason to self-medicate with NSAIDs, aspirin or other anti-inflammatories for low mood. These trials were conducted under supervision, the benefits are modest and population-specific, and long-term NSAID use carries real risks to the stomach, kidneys and heart. If your mood is low, the evidence-based first steps are the standard ones: talk to your GP, and see our overview of low mood versus depression.
Memory, cognition and Alzheimer's
The case that brain inflammation matters for long-term cognition is strongest in Alzheimer's disease, and it comes from an unexpected direction: genetics. For years the field focused on amyloid plaques and tau tangles. But genome-wide association studies have repeatedly turned up risk genes expressed mainly in microglia, the brain's immune cells, pointing to the immune response as a driver rather than a bystander. The standout is TREM2: the R47H variant raises the risk of late-onset Alzheimer's roughly four to fivefold (odds ratio around 4.5), and other immune-related genes such as CD33, CR1 and ABCA7 also feature.9
The current picture is that microglia are double-edged in Alzheimer's. Early on they help clear amyloid; later, chronically activated microglia and astrocytes may accelerate damage to synapses and neurons.1 This is why neuroinflammation is now a serious drug target. It is also why you should be cautious: identifying inflammation as part of the disease does not mean an over-the-counter "anti-inflammatory" approach prevents dementia. That leap is not supported.
Beyond Alzheimer's, observational cohorts link higher midlife inflammatory markers to steeper later cognitive decline, but this is association, not proof, and overlaps with vascular risk. If memory is your concern, our guide to memory loss in older age covers the reversible causes worth checking first, several of which (poor sleep, low mood, thyroid and B12 problems) are far more common and treatable than dementia.
The gut, the vagus nerve and the body-brain loop
The brain does not inflame in isolation. A major route by which the body signals the brain is the vagus nerve, the long wandering nerve connecting the brainstem to the gut and other organs. Around 80% of its fibres are sensory, carrying information up to the brain, including signals about inflammation and gut state.7 This is one way an inflamed or disordered gut can plausibly influence mood and fatigue, and part of the basis for the much-discussed gut-brain axis.
The vagus also runs in the other direction through the cholinergic anti-inflammatory pathway, described by Kevin Tracey and colleagues. Activity in the vagus releases acetylcholine that dampens cytokine release (notably TNF-alpha) from immune cells via alpha-7 nicotinic receptors, effectively turning down peripheral inflammation.8 This is well demonstrated in animals and is the rationale behind experimental vagus nerve stimulation. It is also, predictably, the part most exaggerated online: claims that you can meaningfully "hack your vagus nerve" with breathing apps or cold plunges to control brain inflammation run well ahead of the human evidence. The mechanism is real; the consumer promises are not yet earned. For the calmer, evidence-based version, see our piece on the vagus nerve and autonomic balance.
What raises brain inflammation
Most of the drivers are the same ones that raise inflammation everywhere, which is reassuring, because it means the fixes overlap. The mechanisms below range from well-established to plausible-but-unproven, and it is worth keeping that distinction in mind.
- Poor and disrupted sleep. Sleep disturbance and both short and long sleep track with higher CRP and IL-6 across 72 studies and more than 50,000 people, though the effects are modest and short-term experimental deprivation does not reliably raise these markers.10 Sleep is when the brain's glymphatic clearance system is most active.
- Visceral fat. The deep fat around the organs behaves like an active inflammatory organ, secreting IL-6 and TNF-alpha; these can cross into the brain via saturable transport, and visceral adiposity is linked to poorer hippocampal function and cognitive control.11
- Untreated obstructive sleep apnoea. Repeated overnight drops in oxygen drive systemic inflammation and oxidative stress, and apnoea is consistently associated with cognitive impairment and raised Alzheimer's risk.12
- Chronic psychological stress. Sustained stress and a dysregulated cortisol response are linked to a pro-inflammatory shift; the relationship is bidirectional and tangled with sleep and behaviour.
- Ultra-processed diet. Diets high in refined carbohydrates, industrial fats and ultra-processed foods are associated with higher inflammatory markers, partly through visceral fat and the gut.
- Infection and an ageing immune system. Repeated or chronic infections, and the gradual pro-inflammatory drift of the immune system with age (sometimes called inflammaging), both feed the picture.
What the evidence says helps, and what is just sold
This is where the gap between marketing and evidence is widest. The honest hierarchy puts unglamorous lifestyle levers at the top and most supplements near the bottom. Almost none of these interventions have been shown to lower neuroinflammation directly in living human brains; the evidence is mostly on systemic inflammatory markers, mood, cognition or sleep, which is a reasonable but indirect proxy.
| Lever | What the evidence shows | Strength |
|---|---|---|
| Treating sleep apnoea | CPAP improves some cognitive measures and lowers inflammatory markers in moderate-to-severe OSA.12 | Moderate (treats a clear cause) |
| Regular exercise | Meta-analyses of randomised trials show exercise lowers CRP, IL-6 and TNF-alpha across populations.13 | Strong for systemic markers |
| Protecting sleep | Sleep disturbance tracks higher inflammation; better sleep is a reasonable lever, effects modest.10 | Moderate (observational) |
| Reducing visceral fat | Visceral fat actively produces inflammatory cytokines; loss lowers them.11 | Strong mechanistically |
| Mediterranean-style diet | In the SMILES trial, 32% reached remission of depression on a dietary intervention versus 8% in controls.14 | Moderate (small RCT, mood outcome) |
| Omega-3 (EPA) where relevant | Meta-analysis suggests EPA-predominant omega-3 (EPA at least 60%, up to about 1 g/day) modestly helps depression.15 | Modest; adjunct, not a cure |
| Most "anti-neuroinflammatory" supplements | Marketed confidently; human evidence for brain effects is thin or absent. | Weak to none |
A few things stand out. Exercise is the strongest single lever, with consistent randomised-trial evidence that it lowers systemic inflammation.13 Treating sleep apnoea is one of the few interventions that targets a clear, modifiable cause directly. Diet has one supportive randomised trial in depression (SMILES), which is genuinely interesting but small and used a mood outcome, not a brain-inflammation outcome.14 Omega-3 has a modest, EPA-specific signal in depression, best seen as an adjunct.15
Evidence read: the long list of supplements sold as "anti-neuroinflammatory" (high-dose curcumin, lion's mane, various nootropics, megadose antioxidants) rests largely on cell and animal studies, or on systemic markers, with little or no evidence they reduce inflammation in the human brain or improve outcomes that matter. They are not dangerous in most cases, but they are a garnish, not the meal, and the confident marketing is not matched by the data. If you are weighing several at once, our stack builder can help you avoid spending on overlap.
What to ask your GP and what to do next
The most useful move is rarely to chase "neuroinflammation" as a diagnosis (it is not one you can simply test for in clinic) but to address the common, treatable things that drive it and that mimic it.
- I have persistent fatigue, low mood or brain fog. Could sleep apnoea, thyroid problems, low B12, low iron or depression explain it, and can we test for the reversible causes?
- Should my snoring, daytime sleepiness or witnessed pauses in breathing prompt a referral for a sleep study?
- Given my overall risk, is my waist measurement or visceral fat worth addressing?
- If my mood is low, what are the evidence-based options (talking therapy, medication, lifestyle), and is anti-inflammatory treatment relevant only if I have raised inflammation?
- Are any of my current supplements unnecessary or interacting with my medicines?
References
- Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener / Frontiers and Journal of Neuroinflammation reviews. 2020-2025. Springer (J Neuroinflammation 2022).
- Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56. nature.com.
- Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150(3):736-744. PMID 23870425.
- Udina M, Castellvi P, Moreno-Espana J, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(8):1128-1138. PMID 22967776.
- Kohler-Forsberg O, Lydholm CN, Hjorthoj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404-419. PMID 30834514.
- Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. jamanetwork.com.
- Breit S, Kupferberg A, Rogler G, Hasler G. Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front Psychiatry. 2018;9:44. PMC5859128.
- Tracey KJ. The inflammatory reflex and the cholinergic anti-inflammatory pathway (state-of-the-art review). Neurosci Biobehav Rev. 2022;136:104622. sciencedirect.com.
- Ulland TK, Colonna M. TREM2: a key player in microglial biology and Alzheimer disease (and GWAS of innate immune genes). Nat Rev Neurol / Mol Neurodegener. 2018. Mol Neurodegener 2018.
- Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry. 2016;80(1):40-52. PMC4666828.
- Tucsek Z, et al; and Reilly SM, Saltiel AR. Adipose tissue inflammation, the blood-brain barrier and cognition in obesity. PMC reviews. 2021-2022. PMC9002268.
- Bubu OM, Andrade AG, Umasabor-Bubu OQ, et al. Obstructive sleep apnea, cognition and Alzheimer's disease: a systematic review integrating three decades of research. Sleep Med Rev. 2020;50:101250. PMC7593825.
- Multiple meta-analyses of randomised controlled trials on exercise and inflammatory markers (CRP, IL-6, TNF-alpha) in healthy adults and chronic disease. Front Psychol / J Sports Sci. 2023. PMC10499556.
- Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the SMILES trial). BMC Med. 2017;15:23. BMC Medicine.
- Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9:190. nature.com.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.